Metoprolol CR/XL in female patients with heart failure. Analysis of the experience in metoprolol extended-release randomized intervention trial in heart failure (MERIT-HF)

Ghali, Jalal K.; Piña, Ileana L.; Gottlieb, Shmuel; Deedwania, P.; Wikstrand, John

doi:10.1016/s1062-1458(02)00794-8

Cited by 70 publications

(111 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…471 Similarly, in a post hoc analysis of Cardiac Insufficiency Bisoprolol Study (CIBIS) II, a study of bisoprolol added to a diuretic and ACE inhibitors, women not only benefited from beta-blockade, but mortality was significantly lower in women compared with men (HR 0.64; 95% CI 0.47-0.86).…”

Section: Beta-blockersmentioning

confidence: 99%

A comprehensive view of sex-specific issues related to cardiovascular disease

Pilote¹,

Dasgupta²,

Guru³

et al. 2007

Canadian Medical Association Journal

374

256

View full text Add to dashboard Cite

A comprehensive view of sex-specific issues related to cardiovascular disease Cardiovascular disease (CVD) is the leading cause of mortality in women. In fact, CVD is responsible for a third of all deaths of women worldwide and half of all deaths of women over 50 years of age in developing countries. The prevalence of CVD risk factor precursors is increasing in children. Retrospective analyses suggest that there are some clinically relevant differences between women and men in terms of prevalence, presentation, management and outcomes of the disease, but little is known about why CVD affects women and men differently. For instance, women with diabetes have a significantly higher CVD mortality rate than men with diabetes. Similarly, women with atrial fibrillation are at greater risk of stroke than men with atrial fibrillation. Historically, women have been underrepresented in clinical trials. The lack of good trial evidence concerning sex-specific outcomes has led to assumptions about CVD treatment in women, which in turn may have resulted in inadequate diagnoses and suboptimal management, greatly affecting outcomes. This knowledge gap may also explain why cardiovascular health in women is not improving as fast as that of men. Over the last decades, mortality rates in men have steadily declined, while those in women remained stable. It is also becoming increasingly evident that gender differences in cultural, behavioural, psychosocial and socioeconomic status are responsible, to various degrees, for the observed differences between women and men. However, the interaction between sex-and gender-related factors and CVD outcomes in women remains largely unknown. CMAJ 2007;176(6):S1-44 Although cardiovascular disease (CVD) is common, significant sex-related differences in its epidemiology have only recently been appreciated. The objective of this section is to demonstrate that there are sex-specific differences in the prevalence, complications and burden of CVD in terms of mortality, hospital admissions and quality of life. Abstract Search strategyA MEDLINE search was conducted using the MeSH terms "cardiovascular disease" OR "atrial fibrillation" OR "congestive heart failure." A second search used the terms "prevalence" OR "incidence" OR "mortality" and the final search combined the results of the first 2 searches and added the terms "gender" OR "sex." Articles identified in this manner were retrieved and their reference lists searched for additional relevant articles. The search was limited to English-language publications, but no other restrictions were applied. Other data sources included Web sites of the World Health Organization, the Canadian Institute for Health Information and the National Centre for Health Statistics. Thirty-three original studies were reviewed. Studies were included if they were cohort studies, case-control studies or nested cohort studies that examined the incidence, prevalence or mortality of CVD, congestive heart failure or atrial fibrillation. The studies had to include data on both ...

show abstract

Section: Beta-blockersmentioning

confidence: 99%

A comprehensive view of sex-specific issues related to cardiovascular disease

Pilote¹,

Dasgupta²,

Guru³

et al. 2007

Canadian Medical Association Journal

374

256

View full text Add to dashboard Cite

show abstract

“…23 yielded a mortality benefit with β-blockers in women similar to that recorded in men. The relative risk of death was decreased by 31% in women compared with 34% in men, which are both significant findings 21 .…”

Section: Diagnosis and Treatmentmentioning

confidence: 70%

Untitled

2018

SHJ

View full text Add to dashboard Cite

“…In the only post-hoc analysis of the women (n=898) in MERIT-HF, 19 there was a 21% reduction in the primary end point of all-cause mortality and hospitalizations with β-blocker usage, but it did not lead to a significant reduction in mortality when viewed as separate end points. The women in the MERIT-HF study had New York Heart Association (NYHA) class II-IV with a left ventricular ejection fraction (LVEF) <40%, and 58% of them had an ischemic etiology for their CHF.…”

Section: Discussionmentioning

confidence: 92%